Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, randomized, double-blind, active-controlled, parallel group, Phase III Clinical Trial To Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of CKD-701 and Lucentis® in Patients with Neovascular(wet) Age related Macular Degeneration

Clinical Trial Description

Subjects will be randomised in a 1:1 ratio to receive either CKD-701 or Lucentis®. Investigational Products (IP) (CKD-701 or Lucentis®) will be administered once a month during the loading phase(the first three months), and for the next nine months(PRN phase), administion will be determined based on the PRN administration criteria. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04857177
Study type Interventional
Source Chong Kun Dang Pharmaceutical
Status Completed
Phase Phase 3
Start date October 19, 2018
Completion date March 17, 2021